PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33996592-0 2021 Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer. Tamoxifen 77-86 nuclear receptor subfamily 4 group A member 1 Homo sapiens 143-159 33910628-0 2021 Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report. Tamoxifen 78-87 nuclear receptor subfamily 4 group A member 1 Homo sapiens 33-49 33910628-3 2021 We describe the case of a patient who was treated successfully with tamoxifen for her hormone-receptor-positive breast cancer and acromegaly. Tamoxifen 68-77 nuclear receptor subfamily 4 group A member 1 Homo sapiens 86-102 33910628-8 2021 CONCLUSION: This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Tamoxifen 53-62 nuclear receptor subfamily 4 group A member 1 Homo sapiens 91-107 33910628-9 2021 Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. Tamoxifen 20-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 196-212 33910628-10 2021 We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. Tamoxifen 35-44 nuclear receptor subfamily 4 group A member 1 Homo sapiens 104-120 33737962-0 2021 High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. Tamoxifen 10-19 nuclear receptor subfamily 4 group A member 1 Homo sapiens 28-44 33905134-1 2021 The phase 2 LEO study showed that everolimus (EVE) plus letrozole (LET) with ovarian suppression increased progression-free survival (PFS) in tamoxifen-exposed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer with visceral metastases. Tamoxifen 142-151 nuclear receptor subfamily 4 group A member 1 Homo sapiens 185-201 33258078-1 2021 PURPOSE: There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC). Tamoxifen 126-135 nuclear receptor subfamily 4 group A member 1 Homo sapiens 159-175 33258078-1 2021 PURPOSE: There are conflicting results on the potential role of HER2-status on the efficacy of aromatase inhibitors (AIs) and tamoxifen (TAM) in patients with hormone receptor (HR)-positive breast cancer (BC). Tamoxifen 137-140 nuclear receptor subfamily 4 group A member 1 Homo sapiens 159-175 33737962-3 2021 This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR. Tamoxifen 54-63 nuclear receptor subfamily 4 group A member 1 Homo sapiens 142-144 33737962-3 2021 This study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR. Tamoxifen 65-68 nuclear receptor subfamily 4 group A member 1 Homo sapiens 142-144 33737962-14 2021 Conclusion: A high-dose of TAM is effective and safe for patients with advanced breast cancer with high HR expression. Tamoxifen 27-30 nuclear receptor subfamily 4 group A member 1 Homo sapiens 104-106 32926316-1 2020 The primary and secondary benefits of tamoxifen as adjuvant therapy in women with hormone-receptor-positive breast cancer are substantial: a 1% decrease in the risk of death each year for 10 years with each additional year of treatment during the first 5 years. Tamoxifen 38-47 nuclear receptor subfamily 4 group A member 1 Homo sapiens 82-98 33596096-1 2021 BACKGROUND: Tamoxifen and aromatase inhibitors (AIs) are used as adjuvant hormonal therapy (AHT) for early-stage hormone receptor-positive (HR+) breast cancer. Tamoxifen 12-21 nuclear receptor subfamily 4 group A member 1 Homo sapiens 113-129 33547330-1 2021 The PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer. Tamoxifen 156-165 nuclear receptor subfamily 4 group A member 1 Homo sapiens 194-210 33324567-1 2020 Background: Tamoxifen and fulvestrant, both approved for endocrine therapy, have remarkably increased the prognosis of hormone receptor-positive breast cancer patients. Tamoxifen 12-21 nuclear receptor subfamily 4 group A member 1 Homo sapiens 119-135 32352244-0 2020 Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. Tamoxifen 31-40 nuclear receptor subfamily 4 group A member 1 Homo sapiens 69-85 32367072-13 2020 After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32; 95% confidence interval, CI: 0.14-0.74). Tamoxifen 55-64 nuclear receptor subfamily 4 group A member 1 Homo sapiens 126-128 30980508-1 2019 The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. Tamoxifen 85-94 nuclear receptor subfamily 4 group A member 1 Homo sapiens 126-142 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 297-306 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-170 31618131-11 2020 CONCLUSION: Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone. Tamoxifen 275-284 nuclear receptor subfamily 4 group A member 1 Homo sapiens 37-39 31618131-11 2020 CONCLUSION: Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defined by clinicopathologic characteristics, may experience a 10% to 15% absolute improvement in 8-year freedom from distant recurrence with exemestane plus OFS versus tamoxifen plus OFS or tamoxifen alone. Tamoxifen 297-306 nuclear receptor subfamily 4 group A member 1 Homo sapiens 37-39 32398983-1 2020 Tamoxifen is frequently used as adjuvant treatment in premenopausal patients with hormone receptor-positive early breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 82-98 31153828-1 2019 Tamoxifen is the most commonly used endocrine therapy for patients with hormone receptor (HR)-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 72-88 31153828-1 2019 Tamoxifen is the most commonly used endocrine therapy for patients with hormone receptor (HR)-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 90-92 31051411-1 2019 BACKGROUND: Endocrine treatment with Tamoxifen and aromatase inhibitors (AIs) is a staple in the management of hormone receptor positive breast cancer (HR + BC). Tamoxifen 37-46 nuclear receptor subfamily 4 group A member 1 Homo sapiens 111-127 31146160-1 2019 Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive (HER+) breast cancer in both pre- and post-menopausal patients and may undergo metabolic activation in organisms that share similar receptors and thus face comparable mechanisms of response. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 60-77 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 13-22 nuclear receptor subfamily 4 group A member 1 Homo sapiens 150-166 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 13-22 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-170 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 271-280 nuclear receptor subfamily 4 group A member 1 Homo sapiens 150-166 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 271-280 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-170 31618131-1 2020 PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS) or tamoxifen plus OFS versus tamoxifen alone. Tamoxifen 297-306 nuclear receptor subfamily 4 group A member 1 Homo sapiens 150-166 31146160-1 2019 Tamoxifen (TAM) is a first generation-SERM administered for hormone receptor-positive (HER+) breast cancer in both pre- and post-menopausal patients and may undergo metabolic activation in organisms that share similar receptors and thus face comparable mechanisms of response. Tamoxifen 11-14 nuclear receptor subfamily 4 group A member 1 Homo sapiens 60-77 30980508-1 2019 The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. Tamoxifen 85-88 nuclear receptor subfamily 4 group A member 1 Homo sapiens 126-142 30197363-1 2018 Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 52-68 31331091-0 2019 Autoantibodies Specific to ERalpha are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. Tamoxifen 51-60 nuclear receptor subfamily 4 group A member 1 Homo sapiens 75-91 30478785-0 2019 G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen. Tamoxifen 132-141 nuclear receptor subfamily 4 group A member 1 Homo sapiens 57-73 29687661-12 2019 Hormone-receptor-positive breast cancer patients who receive adjuvant endocrine therapy with tamoxifen alone might be candidates for extended endocrine therapy. Tamoxifen 93-102 nuclear receptor subfamily 4 group A member 1 Homo sapiens 0-16 30536272-1 2018 Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 101-117 30536272-1 2018 Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. Tamoxifen 11-14 nuclear receptor subfamily 4 group A member 1 Homo sapiens 101-117 31340867-1 2019 BACKGROUND: Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Tamoxifen 12-21 nuclear receptor subfamily 4 group A member 1 Homo sapiens 66-82 30358233-0 2018 Should addition of five years of ovarian suppression to tamoxifen be "must" for hormone receptor positive and HER-2 positive breast cancer under the age of 35? Tamoxifen 56-65 nuclear receptor subfamily 4 group A member 1 Homo sapiens 80-96 28785180-2 2017 5 years of tamoxifen or an aromatase inhibitor for all patients with HR-positive early breast cancer is considered standard; however, there are now data to support an extended approach using up to 10 years of treatment. Tamoxifen 11-20 nuclear receptor subfamily 4 group A member 1 Homo sapiens 69-71 28601930-8 2017 Within the HR-positive/Her2-negative subtype, more women received gonadotropin-releasing hormone agonist and tamoxifen treatment from 2003 to 2008 compared with 1989 to 2002 (p = 0.001 and p = 0.075, respectively). Tamoxifen 109-118 nuclear receptor subfamily 4 group A member 1 Homo sapiens 11-13 28601930-9 2017 CONCLUSIONS: HR-positive young breast cancer patients have a poorer survival compared with older patients, even with more frequent chemotherapy, but more recent use of tamoxifen and ovarian suppression might improve this outcome in these patients. Tamoxifen 168-177 nuclear receptor subfamily 4 group A member 1 Homo sapiens 13-15 27815995-0 2017 Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen. Tamoxifen 127-136 nuclear receptor subfamily 4 group A member 1 Homo sapiens 74-90 28293118-1 2017 INTRODUCTION AND AIMS: Tamoxifen is an adjuvant drug effective in treating hormone receptor - positive breast cancer. Tamoxifen 23-32 nuclear receptor subfamily 4 group A member 1 Homo sapiens 75-91 28422735-9 2017 Particularly, Oct4 expression was associated with poor clinical outcome in patients with hormone receptor-positive breast cancer treated with tamoxifen. Tamoxifen 142-151 nuclear receptor subfamily 4 group A member 1 Homo sapiens 89-105 26482374-7 2016 RESULTS: We found a positive correlation between the variant GG genotype of CTSO rs10030044 and shorter disease-free survival, or overall survival in hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Tamoxifen 218-227 nuclear receptor subfamily 4 group A member 1 Homo sapiens 150-166 27117241-0 2016 Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option. Tamoxifen 36-45 nuclear receptor subfamily 4 group A member 1 Homo sapiens 83-99 27264120-1 2016 BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. Tamoxifen 95-104 nuclear receptor subfamily 4 group A member 1 Homo sapiens 144-160 27012810-1 2016 Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 81-97 26482374-9 2016 Multivariate Cox regression analysis revealed that this genotype was an independent factor indicating a poor prognosis in hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Tamoxifen 190-199 nuclear receptor subfamily 4 group A member 1 Homo sapiens 122-138 25900861-0 2016 Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. Tamoxifen 90-99 nuclear receptor subfamily 4 group A member 1 Homo sapiens 32-48 25900861-1 2016 BACKGROUND/PURPOSE: Extended hormonal therapy with tamoxifen for > 5 years has improved disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast cancer patients. Tamoxifen 51-60 nuclear receptor subfamily 4 group A member 1 Homo sapiens 148-164 25900861-1 2016 BACKGROUND/PURPOSE: Extended hormonal therapy with tamoxifen for > 5 years has improved disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast cancer patients. Tamoxifen 51-60 nuclear receptor subfamily 4 group A member 1 Homo sapiens 166-168 25900861-10 2016 CONCLUSION: Our findings suggest that HR-positive breast cancer women either aged < 40 years or with positive lymph node status were justified in continuing with tamoxifen therapy for > 5 years. Tamoxifen 165-174 nuclear receptor subfamily 4 group A member 1 Homo sapiens 38-40 26417636-1 2015 Two randomised trials have compared 5 years versus 10 years of tamoxifen therapy following surgery for hormone receptor-positive early breast cancer. Tamoxifen 63-72 nuclear receptor subfamily 4 group A member 1 Homo sapiens 103-119 23184499-0 2014 Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients. Tamoxifen 58-67 nuclear receptor subfamily 4 group A member 1 Homo sapiens 71-87 25471040-3 2014 The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Tamoxifen 68-77 nuclear receptor subfamily 4 group A member 1 Homo sapiens 41-57 25199766-9 2014 Tamoxifen is indicated for premenopausal hormone receptor (HR) positive tumors in 86.5% of cases and aromatase inhibitors (AI"s) for postmenopausal in 86%. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 41-57 25199766-9 2014 Tamoxifen is indicated for premenopausal hormone receptor (HR) positive tumors in 86.5% of cases and aromatase inhibitors (AI"s) for postmenopausal in 86%. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 59-61 24857109-1 2014 Treatment with adjuvant endocrine therapy, including tamoxifen and the aromatase inhibitors, has resulted in notable improvements in disease-free and overall survival for patients with hormone receptor-positive breast cancer. Tamoxifen 53-62 nuclear receptor subfamily 4 group A member 1 Homo sapiens 185-201 24434530-1 2014 The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen 43-52 nuclear receptor subfamily 4 group A member 1 Homo sapiens 119-135 24074783-6 2013 Recent data demonstrating that 10 years of tamoxifen improves outcomes compared to 5 may be particularly beneficial for young women with hormone receptor-positive tumors given the risk benefit profile. Tamoxifen 43-52 nuclear receptor subfamily 4 group A member 1 Homo sapiens 137-153 23904760-2 2013 The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor-positive breast cancer in premenopausal women. Tamoxifen 83-92 nuclear receptor subfamily 4 group A member 1 Homo sapiens 122-138 23904760-13 2013 CONCLUSIONS: In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor-positive breast cancer in premenopausal women were similar. Tamoxifen 93-102 nuclear receptor subfamily 4 group A member 1 Homo sapiens 133-149 23819026-2 2013 In young women with hormone-receptor positive disease, 5 years of adjuvant tamoxifen, with or without ovarian suppression/ablation, is considered the standard endocrine therapy. Tamoxifen 75-84 nuclear receptor subfamily 4 group A member 1 Homo sapiens 20-36 23755153-6 2014 Tamoxifen treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2 and Cyclin D1. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 46-62 23580071-1 2013 Tamoxifen is a widely utilized adjuvant anti-estrogen agent for hormone receptor-positive breast cancer, known to undergo CYP2D6-mediated bioactivation to endoxifen. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 64-80 22068628-1 2011 Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor (HR) positive (HR+) status and, nowadays, are used in the adjuvant and neoadjuvant settings, and first-line therapy for advanced breast cancer. Tamoxifen 74-83 nuclear receptor subfamily 4 group A member 1 Homo sapiens 141-157 23538253-2 2013 Evolving understanding of the metabolism and pharmacogenomics of tamoxifen, an early example of targeted therapy for women with hormone receptor-positive breast cancer, has created decision-making challenges for healthcare providers and their patients. Tamoxifen 65-74 nuclear receptor subfamily 4 group A member 1 Homo sapiens 128-144 23184079-9 2013 Our study supported that hormonal therapy, whether in the form of an aromatase inhibitor or tamoxifen, confers a survival benefit when added to chemotherapy and trastuzumab in patients with HR-positive/HER2-positive primary breast cancer. Tamoxifen 92-101 nuclear receptor subfamily 4 group A member 1 Homo sapiens 190-192 23224235-8 2013 Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 62-78 23997516-16 2012 The standard treatment for all HR positive patients was administration of tamoxifen. Tamoxifen 74-83 nuclear receptor subfamily 4 group A member 1 Homo sapiens 31-33 29702826-2 2012 For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Tamoxifen 86-95 nuclear receptor subfamily 4 group A member 1 Homo sapiens 33-49 22236200-4 2012 Approximately, 90% of patients received adjuvant chemotherapy and hormonal therapy with tamoxifen for hormone-receptor (HR)-positive breast cancer. Tamoxifen 88-97 nuclear receptor subfamily 4 group A member 1 Homo sapiens 102-118 22236200-4 2012 Approximately, 90% of patients received adjuvant chemotherapy and hormonal therapy with tamoxifen for hormone-receptor (HR)-positive breast cancer. Tamoxifen 88-97 nuclear receptor subfamily 4 group A member 1 Homo sapiens 120-122 22610153-4 2012 Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients. Tamoxifen 58-67 nuclear receptor subfamily 4 group A member 1 Homo sapiens 93-109 22610153-4 2012 Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients. Tamoxifen 58-67 nuclear receptor subfamily 4 group A member 1 Homo sapiens 111-113 22622474-3 2012 We reported that high PCNA(+) TAM counts were associated with hormone receptor (HR)-negative, high-grade tumors and early recurrence. Tamoxifen 30-33 nuclear receptor subfamily 4 group A member 1 Homo sapiens 62-78 22622474-3 2012 We reported that high PCNA(+) TAM counts were associated with hormone receptor (HR)-negative, high-grade tumors and early recurrence. Tamoxifen 30-33 nuclear receptor subfamily 4 group A member 1 Homo sapiens 80-82 22688624-1 2012 Tamoxifen is a mainstay in the treatment of hormone-receptor sensitive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 44-60 22531359-1 2012 Tamoxifen is an effective antiestrogen used in the treatment of hormone receptor-positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 64-80 21802721-1 2011 BACKGROUND: As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. Tamoxifen 36-45 nuclear receptor subfamily 4 group A member 1 Homo sapiens 94-110 21185724-1 2011 Tamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 57-73 21170551-2 2011 METHODS: Patients received exemestane or tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer. Tamoxifen 41-50 nuclear receptor subfamily 4 group A member 1 Homo sapiens 75-91 21185724-1 2011 Tamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 75-77 20731528-1 2010 BACKGROUND: The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen. Tamoxifen 68-77 nuclear receptor subfamily 4 group A member 1 Homo sapiens 164-180 19809024-1 2009 CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. Tamoxifen 41-50 nuclear receptor subfamily 4 group A member 1 Homo sapiens 87-103 20700120-3 2010 METHODS: We selected patients treated with tamoxifen (40 mg per day) for hormone receptor-positive MBC from whom a blood sample for pharmacogenetic analysis (CYP2D6*3, *4, *5, *6, *10 and *41) was available. Tamoxifen 43-52 nuclear receptor subfamily 4 group A member 1 Homo sapiens 73-89 20209619-13 2010 Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate. Tamoxifen 46-55 nuclear receptor subfamily 4 group A member 1 Homo sapiens 13-15 20426605-2 2010 Tamoxifen has been the standard adjuvant endocrine therapy for both pre- and post-menopausal women with hormone receptor-positive early breast cancer and remains the standard of care for premenopausal women. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 104-120 20060711-8 2010 Women with hormone-receptor positive tumours, with low levels (-/+/++) of 17HSD1, had a 43% reduced risk of recurrence, when treated with tamoxifen (Hazard Ratio (HR)=0.57; 95% confidence interval (CI), 0.37-0.86; p=0.0086). Tamoxifen 138-147 nuclear receptor subfamily 4 group A member 1 Homo sapiens 11-27 20890549-15 2010 Therefore, for postmenopausal, early breast cancer hormone receptor positive women in Colombia, the cost-effective alternative is tamoxifen used as adjuvant therapy for five years. Tamoxifen 130-139 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-67 20043345-0 2010 Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Tamoxifen 145-154 nuclear receptor subfamily 4 group A member 1 Homo sapiens 47-63 18954499-2 2008 For over 20 years, tamoxifen was the standard adjuvant (postoperative) endocrine treatment for hormone receptor-positive (i.e., endocrine-responsive) early breast cancer. Tamoxifen 19-28 nuclear receptor subfamily 4 group A member 1 Homo sapiens 95-111 19541862-0 2009 Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 41-57 17439837-9 2007 In LNNBCs with positive HR status, HER-2 overexpression and/or amplification confer an aggressive tumor phenotype, and this might be related to tamoxifen unresponsiveness. Tamoxifen 144-153 nuclear receptor subfamily 4 group A member 1 Homo sapiens 24-26 19046107-1 2008 A 5-year regimen of tamoxifen hormone therapy has historically been the recommendation for hormone receptor-positive, postmenopausal women with early-stage breast cancer. Tamoxifen 20-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 91-107 18454044-2 2008 For more than 2 decades, tamoxifen has been the standard endocrine agent for hormone receptor-positive tumors. Tamoxifen 25-34 nuclear receptor subfamily 4 group A member 1 Homo sapiens 77-93 18622910-1 2008 Tamoxifen is the standard treatment in premenopausal hormone-receptor positive breast cancer patients with additional benefit in some of these women by adding ovarian ablation or suppression. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 53-69 18622910-9 2008 In selected postmenopausal patients with hormone-receptor positive disease the use of five years of tamoxifen can still be a viable option. Tamoxifen 100-109 nuclear receptor subfamily 4 group A member 1 Homo sapiens 41-57 17890213-7 2007 Tamoxifen has been the gold standard endocrine therapy for hormone-receptor-positive early breast cancer for many years, and the long-term side effects of this agent are well documented. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 59-75 17450590-0 2007 Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Tamoxifen 134-143 nuclear receptor subfamily 4 group A member 1 Homo sapiens 50-66 17450590-3 2007 The authors conducted a retrospective analysis to identify risk factors of early recurrences in hormone receptor (HR)-positive, postmenopausal women within the first 3 years of adjuvant tamoxifen. Tamoxifen 186-195 nuclear receptor subfamily 4 group A member 1 Homo sapiens 96-112 17450590-3 2007 The authors conducted a retrospective analysis to identify risk factors of early recurrences in hormone receptor (HR)-positive, postmenopausal women within the first 3 years of adjuvant tamoxifen. Tamoxifen 186-195 nuclear receptor subfamily 4 group A member 1 Homo sapiens 114-116 17601725-2 2007 Using a methylation microarray, we analysed 117 candidate genes in hormone receptor-positive tumours from 109 breast cancer patients treated by adjuvant tamoxifen. Tamoxifen 153-162 nuclear receptor subfamily 4 group A member 1 Homo sapiens 67-83 17601725-10 2007 Based on PITX2 methylation, about half of hormone receptor-positive, node-negative breast cancer patients receiving adjuvant tamoxifen monotherapy can be considered low-risk regarding development of distant recurrences and may thus be spared adjuvant chemotherapy. Tamoxifen 125-134 nuclear receptor subfamily 4 group A member 1 Homo sapiens 42-58 17515570-0 2007 Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. Tamoxifen 84-93 nuclear receptor subfamily 4 group A member 1 Homo sapiens 16-32 16760268-1 2006 BACKGROUND: Hormone receptor (HR)-positive breast cancer cells grow through estrogen receptor (ER)-signaling pathways that mediate both genomic and nongenomic actions, which cross-talk with growth factors associated with resistance to tamoxifen. Tamoxifen 235-244 nuclear receptor subfamily 4 group A member 1 Homo sapiens 12-28 16959170-26 2006 We accepted that hormone receptor status (ER) for hormonal therapy such as tamoxifen and prediction of response to trastuzumab by HER2 did not require systematic review, as the mechanism of action of these drugs requires intact receptors. Tamoxifen 75-84 nuclear receptor subfamily 4 group A member 1 Homo sapiens 17-33 16760268-1 2006 BACKGROUND: Hormone receptor (HR)-positive breast cancer cells grow through estrogen receptor (ER)-signaling pathways that mediate both genomic and nongenomic actions, which cross-talk with growth factors associated with resistance to tamoxifen. Tamoxifen 235-244 nuclear receptor subfamily 4 group A member 1 Homo sapiens 30-32 16198568-3 2005 Tamoxifen significantly decreases the risk of recurrence and improves survival in all women with hormone receptor-positive invasive breast cancer, including women 70 years and older. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 97-113 16899609-1 2006 PURPOSE: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of steroid hormone receptor-positive breast cancer, and it still remains important due to its well-documented beneficial effect. Tamoxifen 9-18 nuclear receptor subfamily 4 group A member 1 Homo sapiens 93-109 16446340-1 2006 PURPOSE: Adjuvant chemotherapy followed by tamoxifen is a standard treatment option for women with intermediate or high-risk hormone receptor-positive breast cancer. Tamoxifen 43-52 nuclear receptor subfamily 4 group A member 1 Homo sapiens 125-141 16413707-0 2006 Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? Tamoxifen 5-14 nuclear receptor subfamily 4 group A member 1 Homo sapiens 34-50 16413707-8 2006 CONCLUSIONS: Tamoxifen has a significant affect on hormone receptor expression and markers of apoptosis in endometrial polyps. Tamoxifen 13-22 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-67 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 4-6 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-53 16293862-12 2005 TAM is effective in HR-positive disease, but not in HR-negative disease. Tamoxifen 0-3 nuclear receptor subfamily 4 group A member 1 Homo sapiens 20-22 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-53 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-53 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-53 16293862-9 2005 For HR-positive patients, TAM was beneficial (DFS, HR = 1.32 for no TAM v TAM; 95% CI, 1.09 to 1.61; P = .003; OS, HR = 1.26; 95% CI, 0.99 to 1.61; P = .03), but not for HR-negative patients (DFS, HR = 0.81 for no TAM v TAM; 95% CI, 0.64 to 1.03; OS, HR = 0.79; 95% CI, 0.60 to 1.05). Tamoxifen 26-29 nuclear receptor subfamily 4 group A member 1 Homo sapiens 51-53 16203663-6 2005 It is well established that tamoxifen, a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 132-148 16205597-6 2005 It is well established that tamoxifen (T), a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 136-152 16205597-6 2005 It is well established that tamoxifen (T), a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 154-156 15984106-1 2005 (1) After surgical excision of hormone-receptor-positive non metastatic breast cancer in postmenopausal women, a meta-analysis of 55 trials has shown that adjuvant tamoxifen, 20 mg/day for 5 years, reduces the risk of relapse by 8% and the risk of death by 5% (absolute values). Tamoxifen 164-173 nuclear receptor subfamily 4 group A member 1 Homo sapiens 31-47 15984106-11 2005 (5) Pending results of further clinical trials, tamoxifen remains the first-line adjuvant hormone therapy for most postmenopausal women with hormone-receptor-positive non metastatic breast cancer. Tamoxifen 48-57 nuclear receptor subfamily 4 group A member 1 Homo sapiens 141-157 16203663-6 2005 It is well established that tamoxifen, a selective estrogen receptor modulator (SERM), improves overall survival (OS) in women with hormone receptor (HR) positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 150-152 15632249-2 2005 Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer. Tamoxifen 75-84 nuclear receptor subfamily 4 group A member 1 Homo sapiens 203-219 15632249-2 2005 Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer. Tamoxifen 131-140 nuclear receptor subfamily 4 group A member 1 Homo sapiens 203-219 15193263-2 2004 Here, we generated gene expression profiles of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy. Tamoxifen 142-151 nuclear receptor subfamily 4 group A member 1 Homo sapiens 47-63 15342804-7 2004 CONCLUSIONS: As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly reduces the risk of breast and axillary recurrence after lumpectomy in women with small, node-negative, hormone-receptor-positive breast cancers. Tamoxifen 65-74 nuclear receptor subfamily 4 group A member 1 Homo sapiens 193-209 15347434-1 2004 Tamoxifen is currently a standard of care for postmenopausal patients with breast cancer with hormone receptor-positive tumors who are candidates for adjuvant endocrine therapy. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 94-110 15347435-6 2004 The results of 2 large adjuvant trials using AIs sequentially with tamoxifen in postmenopausal women with early-stage, HR-positive breast cancer have been reported. Tamoxifen 67-76 nuclear receptor subfamily 4 group A member 1 Homo sapiens 119-121 14659138-2 2003 Tamoxifen, a selective estrogen receptor modulator, is the standard endocrine treatment for hormone receptor-positive breast cancer, both in the adjuvant and metastatic settings. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 92-108 14766275-3 2004 METHODS: Microarray-based expression profiling was performed on a series of tamoxifen-associated (N = 10) and matched sporadic cases (N = 29) of endometrial carcinoma. Tamoxifen 76-85 nuclear receptor subfamily 4 group A member 1 Homo sapiens 98-104 14703069-6 2003 In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen. Tamoxifen 166-175 nuclear receptor subfamily 4 group A member 1 Homo sapiens 27-43 14703069-6 2003 In patients with confirmed hormone receptor (HR)-positive tumors, the CB rate was 51.9 and 65.7%, respectively, for anastrozole and 41.6 and 58.7%, respectively, for tamoxifen. Tamoxifen 166-175 nuclear receptor subfamily 4 group A member 1 Homo sapiens 45-47 12791423-2 2003 The use of tamoxifen in women with hormone receptor-positive tumors is a relatively simple therapeutic option considering the favourable toxicity profile, whereas the administration of adjuvant chemotherapy is more complicated and a variety of aspects need to be considered. Tamoxifen 11-20 nuclear receptor subfamily 4 group A member 1 Homo sapiens 35-51 12429630-0 2002 Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Tamoxifen 108-117 nuclear receptor subfamily 4 group A member 1 Homo sapiens 11-27 12429630-2 2002 As a result, only limited data are available on the hormone receptor status of CBCs evolving in tamoxifen-treated patients. Tamoxifen 96-105 nuclear receptor subfamily 4 group A member 1 Homo sapiens 52-68 12429630-3 2002 The aim of our investigation was to evaluate the pattern of hormone receptor status of CBCs in patients treated with adjuvant tamoxifen at our institution. Tamoxifen 126-135 nuclear receptor subfamily 4 group A member 1 Homo sapiens 60-76 12011136-9 2002 CONCLUSION: Vietnamese and Chinese women with hormone receptor-positive operable breast cancer benefit from adjuvant treatment with surgical oophorectomy and tamoxifen. Tamoxifen 158-167 nuclear receptor subfamily 4 group A member 1 Homo sapiens 46-62 12149306-10 2002 A 5-year course of adjuvant tamoxifen remains the standard therapy for women with hormone receptor-positive breast cancer. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 82-98 33805613-1 2021 Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 40-56 11791121-4 2001 (2) Tamoxifen, administered for 5 years, significantly improves long-term survival for women of all age groups with hormone receptor-positive tumors. Tamoxifen 4-13 nuclear receptor subfamily 4 group A member 1 Homo sapiens 116-132 8640701-3 1996 Additional chemotherapy and tamoxifen, in hormone receptor-positive tumors, was used after mastectomy. Tamoxifen 28-37 nuclear receptor subfamily 4 group A member 1 Homo sapiens 42-58 11605012-2 2001 The survival benefit differs considerably between hormone receptor-positive and -negative patients, and it is believed that the effectiveness of adjuvant chemotherapy can be increased by hormonal therapy with tamoxifen. Tamoxifen 209-218 nuclear receptor subfamily 4 group A member 1 Homo sapiens 50-66 12057165-10 2000 Adjuvant hormonal therapy with tamoxifen improves DFS and OS in patients with hormone receptor (HR)-positive tumors, and ovarian ablation should be considered in premenopausal patients with HR-positive tumors and multiple involved nodes or stage IIIB disease. Tamoxifen 31-40 nuclear receptor subfamily 4 group A member 1 Homo sapiens 78-94 12057165-10 2000 Adjuvant hormonal therapy with tamoxifen improves DFS and OS in patients with hormone receptor (HR)-positive tumors, and ovarian ablation should be considered in premenopausal patients with HR-positive tumors and multiple involved nodes or stage IIIB disease. Tamoxifen 31-40 nuclear receptor subfamily 4 group A member 1 Homo sapiens 96-98 10945021-2 2000 Recent development in the field of adjuvant chemo/endocrine therapy is an usage of LH-RH analogue with tamoxifen for premenopausal hormone receptor positive women, and also an emerging role of taxans. Tamoxifen 103-112 nuclear receptor subfamily 4 group A member 1 Homo sapiens 131-147 11556039-7 2000 However, the response elicited in a case of the ER-/PR- phenotype justified the randomized use of tamoxifen among patients in Iraq where the necessary requirements for hormone receptor assessment are almost unavailable. Tamoxifen 98-107 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-184 34209871-0 2021 NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer. Tamoxifen 16-25 nuclear receptor subfamily 4 group A member 1 Homo sapiens 0-5 34463889-0 2022 Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen. Tamoxifen 103-112 nuclear receptor subfamily 4 group A member 1 Homo sapiens 34-50 34402131-15 2021 IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy. Tamoxifen 249-258 nuclear receptor subfamily 4 group A member 1 Homo sapiens 31-47 34402131-15 2021 IMPLICATIONS FOR PRACTICE: The hormone receptor (HRc) subtype was an independent prognostic factor and the estrogen receptor (ER)+/progesterone receptor (PR)+ subtype showed a better survival in ductal carcinoma in situ (DCIS) patients who received tamoxifen therapy. Tamoxifen 249-258 nuclear receptor subfamily 4 group A member 1 Homo sapiens 49-52 34543613-18 2021 Sequential endocrine therapy with tamoxifen for 2-3 years followed by letrozole for 5 years should be considered as one of the optimal standard endocrine treatments for postmenopausal patients with hormone receptor-positive breast cancer. Tamoxifen 34-43 nuclear receptor subfamily 4 group A member 1 Homo sapiens 198-214 34209871-6 2021 Here, we propose that NR4A1 is a promising target to overcome tamoxifen resistance. Tamoxifen 62-71 nuclear receptor subfamily 4 group A member 1 Homo sapiens 22-27 34209871-7 2021 NR4A1 gene expression was downregulated in tamoxifen-resistant MCF7 (TamR) cells compared to that in MCF7 cells. Tamoxifen 43-52 nuclear receptor subfamily 4 group A member 1 Homo sapiens 0-5 34209871-8 2021 Kaplan-Meier plots were used to identify high NR4A1 expression correlated with increased survival rates in patients with ER-positive breast cancer following tamoxifen treatment. Tamoxifen 157-166 nuclear receptor subfamily 4 group A member 1 Homo sapiens 46-51 34209871-9 2021 Gain and loss of function experiments showed that NR4A1 restores sensitivity to tamoxifen by regulating cell proliferation, migration, invasion, and apoptosis. Tamoxifen 80-89 nuclear receptor subfamily 4 group A member 1 Homo sapiens 50-55 34209871-11 2021 In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance. Tamoxifen 79-88 nuclear receptor subfamily 4 group A member 1 Homo sapiens 46-51 34209871-11 2021 In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance. Tamoxifen 79-88 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-173 34868931-1 2021 Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. Tamoxifen 0-9 nuclear receptor subfamily 4 group A member 1 Homo sapiens 70-86 34868931-1 2021 Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. Tamoxifen 11-14 nuclear receptor subfamily 4 group A member 1 Homo sapiens 70-86 34830800-3 2021 RECENT FINDINGS: Tamoxifen, aromatase inhibitors, and fulvestrant are the main drugs that have been used for decades in the therapy of hormone-receptor-positive breast cancer patients. Tamoxifen 17-26 nuclear receptor subfamily 4 group A member 1 Homo sapiens 135-151 34720808-7 2021 However, 15 of the HR+ patients died before tamoxifen became available in 2013. Tamoxifen 44-53 nuclear receptor subfamily 4 group A member 1 Homo sapiens 19-21 34414958-1 2021 BACKGROUND: Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer. Tamoxifen 58-67 nuclear receptor subfamily 4 group A member 1 Homo sapiens 155-171 34414958-1 2021 BACKGROUND: Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer. Tamoxifen 69-72 nuclear receptor subfamily 4 group A member 1 Homo sapiens 155-171 34359587-6 2021 In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. Tamoxifen 127-136 nuclear receptor subfamily 4 group A member 1 Homo sapiens 151-167 34209871-11 2021 In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance. Tamoxifen 203-212 nuclear receptor subfamily 4 group A member 1 Homo sapiens 46-51 34209871-11 2021 In silico and in vitro analyses revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling in ER-positive breast cancer, suggesting that the NR4A1/ERK signaling axis modulates tamoxifen resistance. Tamoxifen 203-212 nuclear receptor subfamily 4 group A member 1 Homo sapiens 168-173 34209871-12 2021 These results indicate that NR4A1 could be a potential therapeutic target to overcome tamoxifen resistance in ER-positive breast cancer. Tamoxifen 86-95 nuclear receptor subfamily 4 group A member 1 Homo sapiens 28-33